Navigation Links
Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
Date:5/22/2008

CAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The fourth clinical stage antibody is MT293 which is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on ou
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
2. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
3. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
4. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
5. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
6. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
7. Micromet Announces Changes in Management Team
8. Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
9. Abbott Presents Long-Term Data From Extension Study Showing Adult Crohns Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
10. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
11. Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015  BC Technical, ... Solutions, has acquired Eclipse Systems, a Nuclear Imaging ... solutions. As part of their ongoing vision to ... an affordable rate, BC Technical continues to expand ... BC Technical to add valuable resources and knowledge ...
(Date:3/2/2015)... -- DURECT Corporation (Nasdaq: DRRX ) announced today ... 2014. Total revenues were $4.3 million for the three ... months ended December 31, 2013.  Net loss was $5.9 ... as compared to a net loss of $5.1 million ... million and net loss was $22.1 million for the ...
(Date:3/2/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported financial ... 31, 2014. Financial highlights for the fourth quarter include revenues ... or $0.04 per share. This compares to revenues of $12.5 ... per share, for the fourth quarter of 2013. Financial highlights ... and a net loss of $68.4 million, or $0.56 per ...
Breaking Medicine Technology:BC Technical Acquires Eclipse Systems 2DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 2DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 3DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 4DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 5DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 6DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 7DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 8DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 9DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 10DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 11DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 12Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 2Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 3Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 4Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 5Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 6Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 7Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 8Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 9
(Date:3/3/2015)... March 03, 2015 HealthCarePoint ... networking-technology corporation, announced today that it has completed ... Clinical Data Interchange Standards Consortium (CDISC). HCP will ... to standardize knowledge-based training and certifications globally. HCP’s ... and web support as well as development of ...
(Date:3/3/2015)... Salt Lake City, UT (PRWEB) March 03, 2015 ... is an innovative, user-friendly website that focuses ... wilderness therapy, therapeutic boarding schools, and addiction treatment ... Additionally, all residential interventions on the site ... assessments, anxiety, ADHD, autism spectrum disorders, severe learning ...
(Date:3/2/2015)... March 02, 2015 Calvary Hospital ... their Brooklyn Satellite in Lutheran Medical Center, with ... award must demonstrate excellence through clinical expertise as ... expected to go above and beyond to make ... with patients and their families. Award recipients are ...
(Date:3/2/2015)... Dr. David Knepp, a leading chiropractor with ... Doctors on Liens to bring his medical team’s ... personal injury victims to have access to multiple specialists ... basis. However, San Diego Chiropractic Group does ... pain management physician, massage, and acupuncture to help aid ...
(Date:3/2/2015)... 1% for the Planet , one of ... over 25 new business members at this year’s Expo West ... 1% for the Planet welcomes them and more, including Boulder ... nut butter line. , Food - how we grow ... continues to be a complex environmental issue throughout the country ...
Breaking Medicine News(10 mins):Health News:HealthCarePoint Completes CDISC BlueCloud Transnational Commerce Through In-kind Donations 2Health News:HealthCarePoint Completes CDISC BlueCloud Transnational Commerce Through In-kind Donations 3Health News:All Kinds of Therapy – New Website for Behavioral Health and Substance Abuse Treatment Launches Today 2Health News:Calvary Hospital Honors Peter Acerios, RN, with Daisy Award 2Health News:Distinguished Doctor Brings His Multi-Specialty Medical Group to Doctors on Liens in San Diego 2Health News:1% For the Planet Members Shine Light on Food as Environmental Issue at Expo West 2Health News:1% For the Planet Members Shine Light on Food as Environmental Issue at Expo West 3
... Testing for the presence of specific cancer protein ,fingerprints, ... a useful means of identifying a subgroup whose tumors ... drug erlotinib, especially when other testing methods are unavailable, ... Lung Cancer Conference in Geneva, Switzerland. Erlotinib is ...
... finds , FRIDAY, April 30 (HealthDay News) -- A shared ... spouses of kidney dialysis patients are at increased risk for ... were surprised to find that the risk of developing chronic ... as high as it is for blood relatives of these ...
... treatment decisions and political advocacy, study finds , FRIDAY, April ... than just their parents in their corner, with a new ... in the lives of kids with the developmental disorder. , ... the care of youngsters with autism. In fact, the report ...
... are known to have a higher risk of cancer, compared ... immunosuppressive drugs to prevent organ rejection. Results published today from ... to increase this cancer risk. Evaluating data from 1983 ... 481 patients over 20 years - providing the strongest evidence ...
... ... ABBY Award winners: A-Life Medical, Inc.; Specialists On Call, Inc.; and VQ OrthoCare, as ... Novasys Medical, Inc. The winners were announced at ABL Organization’s 12th Annual Innovations in ... ...
... with 2 men who had not been helped with ... Injecting a local anesthetic next to a group of ... is a fast-acting and effective way to treat combat-related ... , The 10-minute procedure, called a stellate ganglion block, ...
Cached Medicine News:Health News:Blood test may identify lung cancer patients likely to respond to erlotinib 2Health News:Why Spouses of Dialysis Patients Get Kidney Disease Too 2Health News:Grandparents Play Vital Role for Autistic Children 2Health News:Grandparents Play Vital Role for Autistic Children 3Health News:Cancer risk for kidney transplant 2Health News:ABBY Winners Announced & Honored with 2010 Innovations in Healthcare(SM) Awards 2Health News:ABBY Winners Announced & Honored with 2010 Innovations in Healthcare(SM) Awards 3Health News:Local Anesthetic May Relieve PTSD Symptoms 2
Helveston tying forceps, standard with smooth jaws. For 4-0 to 6-0 sutures....
Anis tying forcep is extra delicate with smooth jaws, curved. For 9-0 to 11-0 sutures....
Curved shafts and tips with 7 mm tying platform. Serrated handle with polished finish. Overall length 4 inches....
Tying forceps with 6.5 mm tying platform. Round handle with flats provide flexibility of round handle with the stability of a flat handle. Curved shafts. Overall length 3.9 inches....
Medicine Products: